Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Tibial nerve stimulation reduces symptoms of overactive bladder, research finds

Beaumont Health System research finds that symptoms of overactive bladder, or OAB, were reduced in those who received tibial nerve stimulation. The three-year results published in the June issue of The Journal of Urology show participants with urinary frequency, urgency and involuntary loss of urine maintained significant improvement in their symptoms.

31 May 2013

Apnix Sleep Diagnostics updates comprehensive sleep apnea treatments

Apnix Sleep Diagnostics has recently updated its comprehensive sleep apnea treatments, and is eager to serve more Houston sufferers of this condition.

31 May 2013

Weekend reading: Mental illness stigma, health insurance mazes and female libido

Linneah sat at a desk at the Center for Sexual Medicine at Sheppard Pratt in the suburbs of Baltimore and filled out a questionnaire. She read briskly, making swift checks beside her selected answers, and when she was finished, she handed the pages across the desk to Martina Miller, who gave her a round of pills.

24 May 2013

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

22 May 2013

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.

20 May 2013

Study: Image-guided brachytherapy prevents growth of cervical tumour in over 90% of patients

Two large, landmark radiotherapy studies have shown that it is possible to treat cervical cancer effectively with high doses specifically adapted to each tumour, and with fewer serious side-effects to the surrounding normal organs.

22 Apr 2013

Study confirms crizotinib drug reduces testosterone levels

A previous study by the University of Colorado Cancer Center reported the common side effect of low testosterone in men treated with the recently approved lung cancer agent, crizotinib.

17 Apr 2013

Review: Impact of TBI on sexuality and importance of rehabilitation strategies

Each year more than three million Americans are living with traumatic brain injury (TBI), a condition that is associated with physical, cognitive, and emotional problems that often affect their sexuality, and subsequently their marital stability, identity, and self-esteem.

7 Apr 2013

Continuous hormone therapy more effective for metastatic prostate cancer

A study published today in the New England Journal of Medicine recommends a dramatic shift in the way doctors treat metastatic prostate cancer.

5 Apr 2013

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat prevalent inflammatory diseases, such as osteoarthritis (Ampion) and diabetic macular edema (Optina) and sexual dysfunction (Zertane) announced FDA acceptance of its POPE questionnaire, a modification of the Premature Ejaculation Profile (PEP) questionnaire that was used in the two successful Zertane Phase 3 clinical trials completed in Europe.

11 Mar 2013

Researchers identify role of Merlin in regulating integrity of axons

One in 25,000 people worldwide is affected by neurofibromatosis type 2 (NF2), a condition where the loss of a tumour suppressor called Merlin results in multiple tumours in the brain and nervous system.

7 Mar 2013

Study finds serious long-term side effects following prostate cancer treatments

A new study comparing outcomes among prostate cancer patients treated with surgery versus radiotherapy found differences in urinary, bowel and sexual function after short-term follow-up, but those differences were no longer significant 15 years after initial treatment.

31 Jan 2013

Sexual dysfunction not determined by hysterectomy technique

The prevalence of hypoactive sexual desire disorder after hysterectomy does not vary with the surgical technique used, researchers report.

15 Jan 2013

LM11A-31 effective at improving limb movement after spinal cord injury in mice

An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows.

10 Jan 2013

Rexahn intends to offer shares of common stock and warrants

Rexahn Pharmaceuticals, Inc. today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering.

29 Nov 2012

Rexahn's quinoxalinyl-piperazine compounds receive U.S. patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company dedicated to developing and commercializing first-in-class oncology therapeutics, today announced that it has been issued a United States patent (No. 8,314,100), titled "1-[6,7-substituted alkoxyquinoxalinyl) aminocarbonyl]-4-(hetero) arylpiperazine derivatives."

21 Nov 2012

Ventus Medical introduces Provent Sleep Apnea Therapy in Canada

Ventus Medical is pleased to announce the introduction of its proprietary Provent Sleep Apnea Therapy into Canada. Provent Therapy is an innovative, non-invasive treatment for obstructive sleep apnea (OSA).

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

9 Nov 2012

Cost of searching for fountain of youth exceeds cost for medications to treat chronic disease

The cost of searching for the fountain of youth has become increasingly expensive and now exceeds the cost for medications used to treat chronic disease, according to new research released today at the American Public Health Association's 140th Annual Meeting in San Francisco, Calif.

31 Oct 2012